What is Inovio Pharmaceuticals's market cap?

Inovio Pharmaceuticals (INO) has a market capitalization of $97.9M and trades on NASDAQ.

Who are Inovio Pharmaceuticals's competitors?

Inovio Pharmaceuticals's key competitors include Precigen, Moderna, BioNTech, and others. These companies compete in similar markets and product categories.

Who does Inovio Pharmaceuticals partner with?

Inovio Pharmaceuticals's notable partners include Coherus BioSciences, Inc., ApolloBio Corporation, AstraZeneca, and others.

Where is Inovio Pharmaceuticals headquartered?

Inovio Pharmaceuticals is headquartered in United States of America and employs approximately 122 people. It has been publicly traded since 1998.

Inovio Pharmaceuticals

INO

Market cap

$97.91M+38.2%

Table of contents

Earnings

Q1 2026 report

May 13, 2026

EPS-$0.28Beat by $0.02

Read the full report

Next report

Aug 12, 2026 (in a month)

Revenue estimate$533.3K

EPS estimate-$0.28

Competitors

By market cap

Moderna$30.4B+163%

Precigen$2.0B+320%

ProShares UltraPro Short NASDAQ Biotechnology$1.9B—

Indaptus Therapeutics, Inc.$333.1M+5,136%

Inovio Pharmaceuticals$97.9M+101%

IN8bio$13.4M+85.6%

Imunon, Inc.$8.4M-43.1%

LIM

Liminatus Pharma, Inc. Class A Common Stock$7.6M-95.9%

By revenue growth

Precigen+376%

Moderna-30.0%

By net margin

Moderna-143.55%-37.9pp

Precigen-3,655.99%+2,037pp

Profile

Inovio Pharmaceuticals is a clinical-stage biotechnology company developing a new class of DNA medicines designed to treat and protect against HPV-associated diseases, cancer, and infectious diseases. The company's platform utilizes proprietary DNA plasmids that act as genetic software to instruct cells to produce disease-fighting proteins, delivered via its specialized CELLECTRA electroporation devices. Their lead candidate, INO-3107, is currently under FDA review for the treatment of recurrent respiratory papillomatosis (RRP).

Competitive position

A pioneer in DNA-based immunotherapy utilizing a proprietary drug-device combination platform to overcome traditional delivery barriers.

GeographiesUnited States, European Union, China

Customer segmentsPatients with rare diseases, Oncology centers, Government defense and health agencies

Business modelR&D intensive, Licensing and Royalties, Collaborative Research

SuppliersContract manufacturing organizations (CMOs), Bacterial fermentation providers, Electronic component suppliers, Academic research institutions

CustomersSpecialty pharmacies, Hospitals and surgical centers, Government health departments, Strategic pharmaceutical partners

CountryUnited States of America

Listed1998

Employees122.0

CEOJacqueline E. Shea

SectorHealthcare

IndustryBiotechnology

Websiteinovio.com

FilingsSEC EDGAR

Questions, answered.

What is Inovio Pharmaceuticals's market cap?: Inovio Pharmaceuticals (INO) has a market capitalization of $97.9M and trades on NASDAQ.
Who are Inovio Pharmaceuticals's competitors?: Inovio Pharmaceuticals's key competitors include Precigen, Moderna, BioNTech, and others. These companies compete in similar markets and product categories.
Who does Inovio Pharmaceuticals partner with?: Inovio Pharmaceuticals's notable partners include Coherus BioSciences, Inc., ApolloBio Corporation, AstraZeneca, and others.
Where is Inovio Pharmaceuticals headquartered?: Inovio Pharmaceuticals is headquartered in United States of America and employs approximately 122 people. It has been publicly traded since 1998.